(Q36819669)

English

The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature

scientific article published on June 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

0 references

The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Patricia A Fetsch

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Andrea Abati

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

publication date

1 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Diagnostic Cytopathology

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

319-328

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

21 January 2018

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

21 January 2018

Assessment of thin-layer breast aspirates for immunocytochemical evaluation of HER2 status

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

21 January 2018

Food and Drug Administration regulation of in vitro diagnostic devices

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

21 January 2018

Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of HER2 status in breast cancer: why, when and how?

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

The predictive value of HER2 in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

What can we learn from Herceptin trials in metastatic breast cancer?

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab-based combination therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of HER2 testing

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing for HER2 status

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Current use of HER2 tests.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of HER2 testing: caught between a rock and a hard place

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical evaluation of HER-2 status: which test to use?

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FDC.20638

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DC.20638

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36819669&oldid=1672285505"